CalliSpheres载药微球在中晚期非小细胞肺癌合并咯血中的应用效果  

Application Effect of CalliSpheres Drug-loaded Microspheres in the Treatment of Advanced Non-small Cell Lung Cancer Complicated with Hemoptysis

作　　者：江强[1] 黄燕群[1] 王红珍 许玉华[1] JIANG Qiang;HUANG Yanqun;WANG Hongzhen;XU Yuhua(Jiangxi Provincial Chest Hospital,Nanchang 330000,China;不详)

机构地区：[1]江西省胸科医院,江西南昌330000

出　　处：《中国医学创新》2022年第19期9-12,共4页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(20204746)。

摘　　要：目的:研究CalliSpheres载药微球在中晚期非小细胞肺癌(NSCLC)合并咯血中的应用效果。方法:选择2019年6月-2020年12月于江西省胸科医院治疗的60例中晚期NSCLC合并咯血患者,按随机数字表法将其分为两组,各30例。观察组采用CalliSpheres载药微球经支气管动脉化疗灌注栓塞术治疗,对照组采用支气管动脉栓塞术、化疗治疗。比较两组临床疗效、止血效果、肿瘤标志物、不良反应及生存率。结果:观察组治疗总有效率为73.33%,高于对照组的46.67%,治疗后观察组癌胚抗原(CEA)为(7.94±2.55)ng/mL,低于对照组的(10.62±2.71)ng/mL,差异均有统计学意义(P<0.05);两组止血总有效率、恶心、呕吐、发热、疼痛、呼吸困难、胸痛发生率及生存率比较,差异均无统计学意义(P>0.05)。结论:中晚期NSCLC合并咯血患者采用CalliSpheres载药微球治疗安全可行,可控制咯血,降低CEA水平,提高中晚期NSCLC治疗效果,可为中晚期NSCLC合并咯血患者提供临床实践依据。Objective:To study the application effect of CalliSpheres drug-loaded microspheres in the treatment of advanced non-small cell lung cancer(NSCLC)with hemoptysis.Method:A total of sixty patients with advanced NSCLC complicated with hemoptysis who were treated in Jiangxi Provincial Chest Hospital from June 2019 to December 2020 were selected and divided into two groups according to the random number table method,with 30 cases in each group.The observation group was treated with CalliSpheres drug-loaded microspheres transbronchial arterial chemoembolization,while the control group was treated with bronchial arterial embolization and chemotherapy.The clinical efficacy,hemostatic effect,tumor markers,adverse reactions and survival rates were compared between the two groups.Result:The total effective rate in the observation group was 73.33%,higher than 46.67%in the control group.After treatment,the carcinoembryonic antigen(CEA)in the observation group was(7.94±2.55)ng/mL,lower than(10.62±2.71)ng/mL in the control group,the differences were statistically significant(P<0.05);there were no significant differences in the total effective rate of hemostasis,the incidences of nausea,vomiting,fever,pain,dyspnea,chest pain and survival rate between the two groups(P>0.05).Conclusion:It is safe and feasible to use CalliSpheres drug-loaded microspheres to treat patients with advanced NSCLC complicated with hemoptysis,which can control the hemoptysis,reduce the level of CEA,and improve the treatment effect of advanced NSCLC.

关 键 词：中晚期非小细胞肺癌 咯血 CalliSpheres载药微球 经支气管动脉化疗灌注栓塞 止血效果 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]